Trial Profile
A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs MRNA-1944 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Moderna Therapeutics
- 05 Jul 2021 Status changed from active, no longer recruiting to completed.
- 29 Oct 2020 According to the Moderna Therapeutics media release, positive interim data from this study was presented at Moderna's annual R&D Day.
- 20 Oct 2020 Planned End Date changed from 1 Sep 2020 to 30 Jun 2021.